The answer to the How?
Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.
We can support you and your company with efficient, key-in hand Pricing and Market Access services that you as our client, as a patient, a physician, as health technology evaluator and a decision maker in the healthcare environment will regard as creative, focused, valuable and excellent.
Service offerings for your benefit:
Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.
European market access challenges usually have acronyms: NICE, HAS, AMNOG, AIFA and CIMP – which give evidence of the global megatrend for rigorous assessments in reimbursement decisions of health technologies (Health Technology Assessment (HTA)).
It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources.